Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $2.2 million.

  • Amphastar Pharmaceuticals' Interest & Investment Income fell 745.78% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 1953.31%. This contributed to the annual value of $10.6 million for FY2024, which is 9439.46% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Interest & Investment Income stood at $2.2 million, which was down 745.78% from $1.9 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Interest & Investment Income's 5-year high stood at $3.3 million during Q2 2024, with a 5-year trough of $141000.0 in Q3 2021.
  • Its 5-year average for Interest & Investment Income is $1.3 million, with a median of $1.0 million in 2023.
  • In the last 5 years, Amphastar Pharmaceuticals' Interest & Investment Income skyrocketed by 41049.72% in 2023 and then tumbled by 4243.33% in 2025.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Interest & Investment Income stood at $157000.0 in 2021, then skyrocketed by 269.43% to $580000.0 in 2022, then soared by 297.07% to $2.3 million in 2023, then dropped by 0.48% to $2.3 million in 2024, then decreased by 2.01% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $1.9 million for Q2 2025, and $2.1 million during Q1 2025.